Search
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalIt is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigationalThey were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240] … [A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant.
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigational[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.
Ethynodiol diacetate
go.drugbank.com/drugs/DB00823ApprovedAlthough etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug
Categories: Sex Hormones and Modulators of the Genital SystemNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.
Categories: Integrin Receptor AntagonistPhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalIt has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … There is an evidence of P188 increasing the structural stability and resealing of the plasma membrane via direct incorporation into the phospholipid bilayer [A27217].
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant, an NK3 receptor antagonist, was developed in response to this issue as well as more understanding of the role of NK3R in the hypothalamic-pituitary-gonadal (HPG) axis. … [A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics
Categories: Neurokinin 3 Receptor AntagonistAmantadine
go.drugbank.com/drugs/DB00915ApprovedInvestigationalAn antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. … The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Mixtures: ROSEL-TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, NMDA Receptor Antagonists